Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7444973 |
Synonyms | |
Therapy Description |
RO7444973 is a bispecific T-cell engaging antibody that targets MAGE-A4 and CD3, which potentially leads to activation and targeting of cytotoxic T-lymphocytes to tumor cells expressing MAGE-A4, resulting in tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7444973 | RO-7444973|RO 7444973 | RO7444973 is a bispecific T-cell engaging antibody that targets MAGE-A4 and CD3, which potentially leads to activation and targeting of cytotoxic T-lymphocytes to tumor cells expressing MAGE-A4, resulting in tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05129280 | Phase I | RO7444973 + Tocilizumab RO7444973 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | Terminated | USA | GBR | ESP | DNK | BEL | AUS | 0 |